Key result
Aspirin remains a key prophylactic for MACE while under investigation as a cancer adjunct.
Why the study?
Aspirin's modern utility relies on its efficacy and safety balance in a contemporary population with falling MACE rates and competing therapeutic agents.
Aspirin's role in contemporary medicine continues to evolve, balancing its efficacy and safety for MACE prophylaxis against competing agents, with potential future applications in cancer chemoprophylaxis.
Aspirin use for MACE warrants ongoing safety review; leaves open cancer chemoprophylaxis as hypothesis-generating.
Aspirin is a foundation drug of the pharmaceutical industry originally derived as an analgesic/anti-inflammatory agent but serendipitously discovered to have use as a prophylactic drug for major adverse cardiovascular events (MACE). Its modern-day utility in this latter role relies on its efficacy/safety balance in a contemporary population where, at least in high-income countries, age-standardised incident rates for MACE are falling, and where there are now competing therapeutic agents. Its future may be determined by its potential role as a chemoprophylactic or adjunct agent for cancer or other disease states. It therefore will continue to be the subject of further clinical research.
No takes yet. Share an insight, caveat, or question.
Nelson et al. (2024) conducted a review in Major adverse cardiovascular events (MACE). Aspirin was evaluated. Aspirin remains a key prophylactic drug for major adverse cardiovascular events and is being investigated for its potential role as a chemoprophylactic or adjunct agent for cancer.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: